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Abstract It has recently been proposed that doxorubicin 
(DOX) can induce apoptosis in human T-leukemia cells via the 
Fas/FasL system in an autocrine/paracrine way. We show here 
that treatment of Jurkat cells with either anti-Fas antibodies, 
anthracyclin drugs or actinomycin D induces the activation of 
CPP32 (caspase-3) and apoptosis. However, DOX treatment did 
not induce the expression of membrane FasL or the release of 
soluble FasL and co-incubation with blocking anti-Fas antibodies 
prevented Fas-induced but not DOX-induced apoptosis. All the 
morphological and biochemical signs of apoptosis induced by 
anti-Fas or DOX can be prevented by Z-VAD-fmk, a general 
caspase inhibitor. DEVD-cho, a specific inhibitor of CPP32-like 
caspases which completely blocks Fas-mediated apoptosis, 
prevented drug-induced nuclear apoptosis but not cell death. 
We conclude that: (i) DOX-induced apoptosis in human T-
leukemia/lymphoma is Fas-independent and (ii) caspase-3 is 
responsible of DOX-induced nuclear apoptosis but other Z-
VAD-sensitive caspases are implicated in cell death. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The mechanism of the cytotoxicity of anthracyclin antibi-
otics on tumor cells has long been a matter of debate. Re-
cently it has been proposed that these and other cytotoxic 
drugs exert their effects by inducing the resident program of 
cell death known as apoptosis [1,2]. One of the most studied 
apoptotic pathways is that triggered by the ligation of the 
plasma membrane molecule Fas (APO-1/CD95). When Fas 
is trimerized by its natural ligand, FasL, either in soluble 
form [3] or expressed in the membrane of effector cells [4], 
or by cytotoxic agonistic antibodies [5], several intracellular 
adapter proteins are recruited to the clustered receptors. These 
molecules, known as FADD/MORT1 [6], bind to intracellular 
Fas domains, known as death domains, and recruit one or 
several cysteine proteases with Asp specificity (caspases), 
such as caspase-8 (FLICE/MACH/Mch-5) or caspase-10 
(FLICE2/Mch-4) [7-9]. The recruitment of these proteases 
induces their autocatalytic processing and activation, which 
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finally leads to the cleavage and activation of CPP32-like pro-
teases, the apoptotic executioner. 
It has recently been proposed [10] that doxorubicin- (DOX) 
and methotrexate-induced apoptosis in human T-leukemic 
cells occurs through the up-regulation of membrane Fas and 
the induction of FasL expression, leading to Fas/FasL inter-
action and cell death. However, this mechanism is difficult to 
apply to leukemic cells like LI210 and K562 cells that do not 
express functional Fas [11,12] but are yet sensitive to toxicity 
elicited by anthracyclin drugs [13,14]. We have recently found 
that several Jurkat-derived sublines which have lost the ex-
pression of membrane Fas and cytosolic caspase-3 are also 
resistant to DOX-induced toxicity (Martinez-Lorenzo et a l , 
submitted). The resistance in this case could be due a priori to 
the lack of expression of either Fas, CPP32 or both. We show 
here that anthracyclin drugs as well as actinomycin D induce 
apoptosis in T-leukemia cells upon activation of the CPP32 
protease. All the morphological and biochemical signs of 
apoptosis induced by these drugs can be prevented by treat-
ment of cells with Z-VAD-fmk, a general caspase inhibitor, 
which prevents CPP32 processing and activation, irrespective 
of the expression of functional membrane Fas. Moreover, in 
Jurkat (CD95/Fas+) cells DOX treatment does not induce the 
release of preformed FasL and co-incubation with blocking 
anti-Fas antibodies prevent Fas-induced but not DOX-in-
duced apoptosis. 
2. Materials and methods 
2.1. Materials 
DOX, daunorubicin, actinomycin D, methotrexate, vincristine and 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) 
were products from Sigma (Madrid, Spain). Cytotoxic monoclonal 
anti-human Fas IgM antibody (clone CH-11) was from UBI (Lake 
Placid, NY, USA), non-cytotoxic blocking mouse monoclonal anti-
human Fas IgGl antibody (clone SMI/23) was from Bender (Barce-
lona, Spain) and mouse IgG2a anti-human CPP32 (clone 19), which 
recognizes the 32 kDa proenzyme, from Transduction Laboratories 
(Lexington, KY, USA). V-Acetyl-Asp-Glu-Val-Asp aldehyde 
(DEVD-cho) and benzyloxycarbonyl-Val-Ala-Asp-nuoromethyl-ke-
tone (Z-VAD-fmk) were from Bachem (Bubendorf, Switzerland). 
2.2. Cell proliferation and toxicity assays 
The human T-cell leukemic cell lines Jurkat (clone E6.1) and 
MOLT-4, and the T-lymphoma HUT 78 were from the American 
Type Culture Collection. Cells were routinely cultured at 37°C in 
RPMI 1640 medium supplemented with 5% fetal calf serum, L-gluta-
mine and penicillin/streptomycin (hereafter called complete medium), 
using standard cell culture procedures. In proliferation and toxicity 
assays, cells (5X10° cells/ml) were treated in complete medium with 
either cytotoxic IgM anti-Fas antibody (50 ng/ml) or the indicated 
drug in flat-bottom, 96-well plates (100 ul/well). For apoptosis inhib-
ition assays, cells were preincubated for 3 h with 600 uM DEVD-cho 
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Fig. 1. Neutralizing anti-Fas antibody (SMl/23) prevents Fas-, but 
not DOX-induced apoptosis. Jurkat cells (5X105 cells/ml) were pre-
incubated or not with 100 ng/ml of SMl/23 antibody for 30 min at 
4°C, and then incubated for 21 h with 0.5 uM DOX or 50 ng/ml 
cytotoxic anti-Fas IgM antibody in the presence or absence of SMI/ 
23 antibody, as indicated. Cell viability was determined by the 
MTT assay. 
or for 1 h with 100 |J.M Z-VAD-fmk prior to the addition of drugs. 
Control cultures were treated with the appropriate amount of DMSO 
alone (0.1%, final concentration). Cell viability was determined by a 
modification of the MTT reduction method of Mosmann [15] or by 
the trypan blue exclusion test. Apoptosis was also microscopically 
evaluated by scoring the number of cells exhibiting a blebbing mor-
phology, defined by the appearance of distinct protrusions of the 
plasma membrane and/or vacuolization. Chromatin condensation 
and nuclear fragmentation during apoptosis was evaluated by labeling 
nuclei with p-phenylenediamine (PPDA) in glycerol and visualized by 
fluorescence microscopy [16]. After treatments, cells (5X105) were 
fixed with 1% paraformaldehyde in PBS, pH 7.4 at room temperature 
for 15 min. Then, cells were washed with PBS and centrifuged onto 
round coverglasses, previously treated for 20 min with 100 ul of a 
sterile solution of poly-L-lysine in distilled water. Dried coverglasses 
containing fixed cells were placed onto a drop of PPDA stain (1 mg/ 
ml PPDA in PBS/oxidized glycerol, 1/5), and analyzed by fluorescence 
microscopy. 
The possible implication of FasL in DOX-induced apoptosis was 
evaluated by using the blocking anti-Fas antibody SMl/23. Cells 
(2.5 XlO5 cells/ml) were preincubated at 4°C for 30 min in PBS+1% 
BSA, pH 7.4, containing or not (controls) 100 ng/ml of the SMl/23 
antibody. Then cells were resuspended at 5xl05/ml in complete me-
dium containing the same amount of blocking anti-Fas antibody, and 
treated with 50 ng/ml of cytotoxic IgM anti-Fas antibody or 0.5 |xM 
DOX at 37°C for 21 h. Then cells were collected by centrifugation and 
viability determined by the MTT assay and by trypan blue staining. 
The possibility that DOX could induce cell death via the release of 
soluble FasL was analyzed as follows: Jurkat cells were treated with 
1 uM DOX in complete medium for 5 h. Cells were recovered by 
centrifugation, washed with cold RPMI medium, resuspended at 
5X 105 cells/ml in complete medium and cultured for 1, 24 or 48 h. 
Culture supernatants were obtained by centrifugation and their tox-
icity was evaluated in a sensitive bioassay using untreated Jurkat cells 
as targets [3]. 
2.3. Flow cytometry analysis 
Fas membrane expression was analyzed with a FITC-labeled anti-
human Fas antibody (Bender, Barcelona, Spain). Cells (5 X105 in 50 
ul) were incubated at 4°C with 5 ng/ml of the antibody in PBS con-
taining 0.2% BSA and 0.02% sodium azide for 1 h. Cells were washed 
with PBS, fixed with 1% paraformaldehyde in PBS, pH 7.4, for 15 min 
and 5000 cells/sample analyzed in an Epics XL-MCL (Coulter, Spain) 
flow cytometer. Phosphatidylserine (PS) exposure during apoptosis 
was evaluated by annexin V-FITC staining [17]. Briefly, cells were 
washed with PBS and incubated in a solution of 0.5 ng/ml FITC-
labeled annexin V in binding buffer (140 mM NaCl, 2.5 mM CaCl2, 
10 mM HEPES/NaOH, pH 7.4) at 4°C for 30 min. Then, cells were 
centrifuged, washed, resuspended in 1 ml of binding buffer and ana-
lyzed by flow cytometry. 
2.4. Analysis of CPP32 activation 
CPP32 activation was evaluated by Western blot analysis of cell 
homogenates with a specific anti-CPP32 antibody. Jurkat cells 
(5XlO5 cells/ml) were incubated in complete medium with one of 
the following drugs: DOX (1 uM), daunorubicin (1 uM), actinomycin 
D (1 |ig/ml), methotrexate (50 and 100 ng/ml) or vinblastine (10 ng/ 
ml). At the times indicated, cell viability was determined by trypan 
blue staining and cells were recovered by centrifugation, washed twice 
with cold PBS and lysed in 1 ml of lysis buffer (0.15 M NaCl, 1 mM 
EDTA, 30 mM NaF, 10 ug/ml leupeptin, 1 mM PMSF, 50 mM Tris-
HC1, pH 7.6, containing 1% Triton X-100) [18], Solubilized proteins 
were resolved by SDS-10% PAGE and transferred to nitrocellulose 
membranes (Hybond-C extra, Amersham). Membranes were sequen-
tially incubated with 50 ng/ml anti-CPP32 antibody and with 0.2 u,g/ 
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Fig. 2. Neutralizing anti-Fas antibody does not block DOX-induced PS exposure. Jurkat cells treated as in Fig. 1 were analyzed for PS expo-
sure by measuring annexin V-FITC binding by flow cytometry. Cells were cultured in medium alone (a-c), or in medium containing 100 ng/ml 
anti-Fas IgGl antibody (SMl/23) (d-f), and treated with 50 ng/ml anti-Fas antibody (b, e) or 1 uM DOX (c, f)-
362 S. Gamen et al.lFEBS Letters 417 (1997) 360-364 
ml goat anti-mouse IgG coupled to alkaline phosphatase (Sigma) and 
revealed with the BCIP/NBT substrate. 
3. Results 
3.1. DOX-induced apoptosis does not involve Fas triggering 
It has recently been proposed that the Fas/FasL system 
could be involved in the cytotoxicity exerted by several drugs, 
including DOX [10]. To test this hypothesis, apoptosis was 
induced in Jurkat cells by DOX treatment in the presence 
or absence of an anti-Fas blocking antibody (SMI/23). To 
assess the blocking activity of this antibody, cells were also 
treated with a cytotoxic monoclonal anti-human Fas IgM 
antibody (CH-11). After 21 h of incubation, cell viability 
was determined and the PS translocation analyzed by annexin 
V-FITC binding. As shown in Fig. 1, while all the cytotoxicity 
induced by CH-11 antibody was prevented by the blocking 
antibody, there was no inhibition of DOX-induced cell death. 
Treatment of Jurkat cells with CH-11 antibody or DOX in-
duced the early exposure of PS on the cell membrane. PS 
exposure was totally inhibited by the blocking antibody in 
CH-11-treated cells while no inhibition could be seen in cells 
incubated with DOX (Fig. 2). We next tested if treatment of 
Jurkat cells with DOX induced the release of soluble FasL to 
the culture medium, which is the main mediator of activation-
induced cell death in these cells [3]. Jurkat cells were treated 
for 5 h with 1 uM DOX, washed, and cultured in fresh me-
dium for 1, 24 or 48 h and culture supernatants collected by 
centrifugation. Untreated Jurkat cells were resuspended in 
these supernatants and cell viability was determined by the 
MTT assay after 24 h of culture. Although cells pretreated 
with DOX died after 24-48 h of culture, none of their culture 
supernatants was toxic for untreated Jurkat cells (data not 
shown). We also evaluated the sensitivity of MOLT-4 and 
HUT 78 cells to DOX-induced apoptosis. According to pre-
vious data [19], MOLT-4 cells expressed Fas membrane levels 
similar to that of Jurkat cells (data not shown), but MOLT-4 
cells were resistant to anti-Fas-induced apoptosis (Fig. 3). 
Resistance to Fas-mediated apoptosis was not reverted by 
co-treatment with cycloheximide, use of higher antibody con-
centrations and/or longer incubation times (data not shown). 
However, MOLT-4 cells were sensitive to DOX-induced 
apoptosis (Fig. 3). Moreover, the same concentration of 
DOX caused only a slight cytostatic effect on HUT 78 cells, 
+ Dxr +Dnr +Acl +Mtx Vcr 
Fig. 4. DOX, daunorubicin and actinomycin D induce early CPP32 
activation which correlates with cell death. A: Jurkat cells (5X105 
cells/ml) were incubated for 16 h with 1 uM DOX, 1 uM daunoru-
bicin or 1 |J,g/ml actinomycin D or for 24 h with 10 ng/ml vincris-
tine or 100 ng/ml methotrexate, as indicated. Cell proteins were sep-
arated by SDS-10%PAGE and CPP32 activation analyzed by 
immunoblotting using an anti-CPP32 antibody. B: Cell viability of 
the corresponding cells was determined by the MTT assay. 
which were almost as sensitive as Jurkat cells to anti-Fas-
induced apoptosis (Fig. 3). 
3.2. DOX treatment induces early CPP32 activation which 
correlates with cell death 
We studied the implication of CPP32 in cell death induced 
by a number of drugs. First, the type of cell death (apoptosis/ 
necrosis) caused by the different drugs was analyzed by nu-
clear staining with PPDA. In the experimental conditions 
used, DOX, daunorubicin and actinomycin D caused chroma-
tin condensation and nuclear fragmentation in Jurkat cells, 
while methotrexate and vinblastine did not (Fig. 6 and data 
not shown), although there was a considerable amount of cell 
death (Fig. 4). Longer times of incubation (48 h) were needed 
to detect chromatin condensation caused by methotrexate or 
vinblastine (data not shown). CPP32 activation was analyzed 
by Western blotting, using an anti-CPP32 antibody. After 16 
Fig. 3. Z-VAD-fmk prevents DOX- and anti-Fas-induced cell death. 
Jurkat, MOLT-4 or HUT 78 cells (5X105 cells/ml) were preincu-
bated with 100 uM Z-VAD-fmk for 1 h, and then treated with 
1 uM DOX or 50 ng/ml cytotoxic anti-Fas antibodies (Ab) for 16 h, 
as indicated. Cell viability was determined by the MTT assay. Cells 
treated with Z-VAD-fmk alone were used as controls. 
+Mtx +Vcr 
Fig. 5. Methotrexate and vincristine induce late CPP32 activation. 
Jurkat cells were incubated for 48 h with 50 ng/ml methothrexate or 
100 ng/ml vincristine. CPP32 activation was determined as indicated 
in Fig. 4. 
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h incubation with either DOX, daunorubicin or actinomycin 
D, a clear activation of CPP32 (a reduced intensity of the 32 
kDa band in the blot) was observed (Fig. 4A). This correlated 
with the extent of cell death induced by each of these drugs 
(Fig. 4B). Incubation of the cells for 24 h with methotrexate 
or vinblastine did not induce a significant activation of this 
caspase, though the extent of cell death was similar to that 
produced by DOX. However, at longer incubation times (48 
h) with these drugs, which induced a virtually complete cell 
death, a late and partial activation of CPP32 was observed 
(Fig. 5). 
3.3. DOX-induced apoptosis is blocked by peptide inhibitors 
of caspases 
Since a significant correlation between DOX-induced death 
and CPP32 activation appeared, we further studied the impli-
cation of CPP32 in apoptosis induced by this drug. DOX-
induced toxicity was fully inhibited by Z-VAD-fmk, a caspase 
inhibitor of wide specificity, in all cells tested (Fig. 3). Z-
VAD-fmk also prevented Fas-mediated apoptosis in Jurkat 
and HUT-78 cells. Both DEVD-cho, which efficiently inhibits 
-DOX +DOX 
Fig. 6. DEVD-CHO inhibits DOX-induced nuclear apoptosis. Ju-
rkat cells (5X 105 cells/ml) were treated with 1 uM DOX for 16 h in 
the presence or absence of 600 uM DEVD-CHO. Cells were stained 
with PPDA and photographed under fluorescence illumination 
(magnification, X280). A: Untreated cells. B: Cells treated with 
DOX. C: Cells treated with DEVD-CHO and DOX. 
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Fig. 7. Z-VAD-fmk, but not DEVD-CHO, inhibits DOX-induced 
PS exposure. Jurkat cells (5xl05 cells/ml) were preincubated in 
complete medium containing: (a, b) DMSO alone; (c, d) 100 |iM 
Z-VAD-fmk; or (e, f) 600 uM DEVD-CHO, and cultured for 16 h 
in the absence (a, c, e) or presence (b, d, f) of 1 u,M DOX. Binding 
of annexin V-FITC was used as a measure of PS exposure. 
CPP32-like protease activity, and Z-VAD-fmk prevented 
chromatin condensation and nuclear fragmentation induced 
by DOX (Fig. 6 and data not shown). Another hallmark of 
apoptosis, the blebbing of the cell membrane, was assessed by 
light microscopy. DOX treatment induced the appearance of a 
blebbing morphology in most Jurkat cells (62%). Addition of 
Z-VAD-fmk restored normal morphology (3% blebbing cells) 
but a significant proportion of cells treated with DOX in the 
presence of DEVD-cho still showed the characteristic bleb-
bing phenotype (46% of cells). 
The effect of caspase inhibitors on PS translocation induced 
by DOX was also analyzed by annexin-V-FITC staining (Fig. 
7). PS translocation was completely blocked when DOX-
treated cells were incubated with Z-VAD-fmk. However, 
DEVD-CHO did not prevent DOX-induced PS exposure 
(Fig. 7). These results suggest that CPP32-like proteases me-
diate DOX-induced nuclear apoptotic events, but other Z-
VAD-inhibitable caspase(s) are involved in cell death. 
4. Discussion 
Doxorubicin and daunorubicin are currently used in the 
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treatment of acute leukemias, Hodgkin 's disease, sarcomas 
and breast cancer. In spite of their generalized use, the mech-
anism by which they induce cell death remains poorly defined. 
D N A intercalation/binding, inhibition of topoisomerase II, 
free radical generation and damage to cell membranes have 
been proposed as mechanisms by which they could exert their 
cytotoxic effects [20]. However, it seems that D N A intercala-
tion is not necessary for the drugs to induce cell death, since 
TV-trifluoroacetyldoxorubicin-M-valerate or transferrin-DOX 
derivatives can induce cell death without association with 
D N A [21,22]. Recent work from different laboratories 
[10,23,24] indicates that D O X and daunomycin cause apopto-
sis in tumor cells. It has also been proposed that DOX-in-
duced apoptosis is mediated by the activation of the Fas/ 
FasL system [10]. Our present results show that, like FasL 
or agonist anti-Fas antibodies, D O X treatment induces 
CPP32 activation and apoptosis. However, co-incubation 
with blocking anti-Fas antibodies fully protected Jurkat cells 
from anti-Fas- but not from DOX-induced toxicity. This 
blocking antibody has also been proven to prevent the toxicity 
induced by soluble FasL secreted by PHA-stimulated Jurkat 
cells [3]. In addition, MOLT-4 cells, which express membrane 
Fas but are resistant to Fas-mediated apoptosis [19], were 
efficiently killed by DOX. In contrast, H U T 78 cells were 
comparatively insensitive to D O X but were as sensitive as 
Jurkat cells to Fas-induced apoptosis. Therefore, it can be 
concluded that DOX-induced apoptosis occurs independently 
of the activation of the Fas/FasL system since no correlation 
between sensitivity to Fas and D O X was found. 
Inhibition of CPP32 activity with DEVD-cho prevented 
Fas-induced apoptosis, as already reported [5,25]. However, 
this peptide only blocked DOX-induced nuclear apoptosis, 
but not cell death. Both D O X - and Fas-induced apoptosis 
were blocked by Z-VAD-fmk, which prevents CPP32 activa-
tion by inhibiting the activity of FLICE/Mch-5 [9,26], and 
presumably of other caspases. This suggests that the execution 
of DOX-induced apoptosis is mediated by several caspases, 
CPP32 controlling only the formation of apoptotic nuclei. 
This could be achieved through the direct cleavage and acti-
vation of Mch-2 by CPP32 [27]. Mch-2 (caspase-6) [28] spe-
cifically cleaves nuclear lamins [29], which are responsible for 
the maintenance of nuclear shape and are also implicated in 
the interactions between the chromatin and nuclear matrix 
[30]. Daunorubicin, a related anthracyclin, and actinomycin 
D , an inhibitor of transcription, also caused the early activa-
tion of CPP32 which correlated with cell death. This was not 
the case for methotrexate and vincristine, drugs in which a 
delay between the onset of cell death and CPP32 activation 
was observed, reflecting probably their different intracellular 
pathways for apoptosis induction. 
We have recently found that Jurkat-derived sublines that 
have lost membrane Fas expression were resistant to both 
anti-Fas and DOX-induced apoptosis. In these sublines, the 
loss of Fas was also accompanied by the loss of CPP32 ex-
pression and, presumably, of other Z-VAD-sensitive caspases 
(Martinez-Lorenzo et al., submitted). A similar phenomenon 
may have been the cause of the apparent causal link pre-
viously observed between Fas and DOX-induced apoptosis 
[10]. 
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